I-8 Balancing Efficacy and Safety for Anxiolysis, Analgesia and Patient Cooperation During Dental Outpatient Procedures

5 (1 vote)

CE Hours: 1.5

Description: The goal of outpatient regimens for anxious dental patients is often described as 'sedation', a non-specific decrease in consciousness and patient responsiveness which is often accompanied by respiratory depression. The patient perspective suggests that reduction in anxiety and minimal pain during the procedure are more specific outcomes that can be accomplished with drugs that produce negligible CNS depression: benzodiazepines, effective local anesthesia and nitrous oxide. This presentation will describe the scientific evidence to support safe pharmacologic strategies for outpatient procedures without the risks of parenteral drug administration or additive drug combinations that incrementally reduce safety with little benefit to the patient.

Learning Objectives:  

  • Identify the major variable that contributes to therapeutic efficacy and sedation for outpatient sedation procedures in dental offices
  • Identify the drugs, doses and routes of administration that optimize the balance between safety and therapeutic success
  • Identify the benefits of having an appropriately trained clinician to monitor the patient, administer the anxiolytic agents and manage adverse events independent of the clinician performing the dental procedure

Key:

Complete
Failed
Available
Locked
I-8 Balancing Efficacy and Safety for Anxiolysis, Analgesia and Patient Cooperation During Dental Outpatient Procedures
Recorded 05/06/2023  |  90 minutes
Recorded 05/06/2023  |  90 minutes
Evaluation
8 Questions
CE Test
5 Questions  |  Unlimited attempts  |  4/5 points to pass
5 Questions  |  Unlimited attempts  |  4/5 points to pass
Certificate
1.00 CE credit  |  Certificate available
1.00 CE credit  |  Certificate available

Raymond Dionne, D.D.S., M.S. Ph.D.

Dr. Dionne received a DDS from Georgetown University and a PhD from the Medical College of Virginia. He conducted clinical and translational pain research at the National Institute of Dental and Craniofacial Research for 34 years, as well as practiced dentistry part-time in the District of Columbia. He is currently a restless retiree living in Missouri.

Speaker Disclosure

In accordance with this policy, I declare I have a past or present proprietary or relevant financial relationship or receive gifts in kind (including soft intangible remuneration), consulting position or affiliation, or other personal interest of any nature or kind in any product, service, course and/or company, or in any firm beneficially associated therewith, as indicated: AIM Targeted Therapeutics: Consultant on preclinical development of an investigational analgesic formulation (Ongoing); Rilento Pharma: consultant for pre-clinical development of investigational analgesic formulation (Ongoing)